<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>20/20 Biolabs, Inc. — News on 6ix</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock</link>
<description>Latest news and press releases for 20/20 Biolabs, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 22 May 2026 12:31:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/2020-biolabs-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69bfa1c78522ec3de04fb7dd.webp</url>
<title>20/20 Biolabs, Inc.</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock</link>
</image>
<item>
<title>20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-commences-emergency-planning-for-ebola-and-hantavirus-lab-testing-if-outbreak-creates-overflow-demand</link>
<guid isPermaLink="true">https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-commences-emergency-planning-for-ebola-and-hantavirus-lab-testing-if-outbreak-creates-overflow-demand</guid>
<pubDate>Fri, 22 May 2026 12:31:00 GMT</pubDate>
<description>Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) (“20/20 Biolabs” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced that it is developing contingency plans to establish Ebola and Hantavirus testing in its CAP-accredited CLIA laborato</description>
</item>
<item>
<title>20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-reports-first-quarter-2026-financial-results-and-recent-operational-progress</link>
<guid isPermaLink="true">https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-reports-first-quarter-2026-financial-results-and-recent-operational-progress</guid>
<pubDate>Wed, 20 May 2026 20:05:00 GMT</pubDate>
<description>State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent Strategic Wins Include Evexia Diagnostics Distribution Agreement, ROKIT Healthcare CKD License, and Commercial Launch of OneTest™ for Longevity GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant</description>
</item>
<item>
<title>20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-exclusively-licenses-psa-velocity-algorithm-from-the-university-of-south-carolina</link>
<guid isPermaLink="true">https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-exclusively-licenses-psa-velocity-algorithm-from-the-university-of-south-carolina</guid>
<pubDate>Tue, 12 May 2026 12:31:00 GMT</pubDate>
<description>Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repeat Blood Test Results Licensing Agreement Expands 20/20 BioLabs’ AI-Enabled Multi-Cancer Early Detection Platform GAITHERSBURG, Md., May 12, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered</description>
</item>
<item>
<title>HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock/news/healwell-to-participate-in-upcoming-2026-bloom-burton-and-co-healthcare-investor-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/2020-biolabs-inc-common-stock/news/healwell-to-participate-in-upcoming-2026-bloom-burton-and-co-healthcare-investor-conference-1</guid>
<pubDate>Mon, 13 Apr 2026 11:00:00 GMT</pubDate>
<description>2026 Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026, in Toronto, ONToronto, Ontario--(Newsfile Corp. - April 13, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce that the Company will be participating as a presenting company at the 2026 Bloom Burton & Co. Healthcare Investor Conference. James Lee, CEO and Dr. Alexander Dobranowski, President,</description>
</item>
<item>
<title>20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-selected-by-evexia-diagnostics-to-offer-onetesttm-for-cancer-through-evexia-platform</link>
<guid isPermaLink="true">https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-selected-by-evexia-diagnostics-to-offer-onetesttm-for-cancer-through-evexia-platform</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Joint Release Expands 20/20 BioLabs’ Testing Solutions Across Evexia’s Network of ~40,000 Functional and Integrative Medicine Practitioners Marks a Commercial</description>
</item>
<item>
<title>20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-reports-full-year-2025-financial-results-and-recent-operational-progress</link>
<guid isPermaLink="true">https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-reports-full-year-2025-financial-results-and-recent-operational-progress</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps State-Funded Firefighter</description>
</item>
<item>
<title>Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock/news/maryland-fire-departments-awarded-dollar520000-for-cancer-screenings-using-2020-biolabs-onetest-tm-multi-cancer-early-detection-blood-test</link>
<guid isPermaLink="true">https://6ix.com/company/2020-biolabs-inc-common-stock/news/maryland-fire-departments-awarded-dollar520000-for-cancer-screenings-using-2020-biolabs-onetest-tm-multi-cancer-early-detection-blood-test</guid>
<pubDate>Fri, 27 Mar 2026 12:31:00 GMT</pubDate>
<description>State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that 18 groups of Maryland fire departments have been notified that they will collectively be awarded over $520,000 from the Maryland Departme</description>
</item>
<item>
<title>20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-announces-exclusive-us-license-agreement-with-rokit-healthcare-to-integrate-advanced-ckd-prediction-technology-into-its-longevity-test-program</link>
<guid isPermaLink="true">https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-announces-exclusive-us-license-agreement-with-rokit-healthcare-to-integrate-advanced-ckd-prediction-technology-into-its-longevity-test-program</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Inflammatory Biomarker Tracking Predicted to Enhance Response to 3-D Bio-Printed Therapies Expands OneTest for Longevity with Chronic Kidney Disease Risk</description>
</item>
<item>
<title>20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-highlights-advantages-of-its-patented-protein-biomarker-technology-for-multi-cancer-early-detection-in-light-of-recent-studies-4</link>
<guid isPermaLink="true">https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-highlights-advantages-of-its-patented-protein-biomarker-technology-for-multi-cancer-early-detection-in-light-of-recent-studies-4</guid>
<pubDate>Thu, 12 Mar 2026 12:31:00 GMT</pubDate>
<description>Protein Biomarkers May Play an Important Role in Overcoming Limitations of Circulating Tumor DNA for Screening Early-Stage CancersGAITHERSBURG, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today provided an update on its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer early detectio</description>
</item>
<item>
<title>20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-launches-onetest-for-longevity-blood-test-and-chronic-disease-risk-assessment-and-management-solution-built-with-ibm-ai-capabilities</link>
<guid isPermaLink="true">https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-launches-onetest-for-longevity-blood-test-and-chronic-disease-risk-assessment-and-management-solution-built-with-ibm-ai-capabilities</guid>
<pubDate>Wed, 25 Feb 2026 13:31:00 GMT</pubDate>
<description>Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health Insights GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (Nasdaq: AIDX), an early market leader in cutting-edge, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announces the launch and commercial availability of its OneTest for Longevity solution.</description>
</item>
<item>
<title>20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-to-host-virtual-investor-webinar-on-thursday-february-26-2026-at-200-pm-eastern-time</link>
<guid isPermaLink="true">https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-to-host-virtual-investor-webinar-on-thursday-february-26-2026-at-200-pm-eastern-time</guid>
<pubDate>Fri, 20 Feb 2026 13:31:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX), an early market leader in cutting-edge, AI-powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced today that it will hold a virtual investor webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time. 20/20 BioLabs President and CEO Jonathan Cohen will host the webinar to discuss the company’s recent Nasdaq listing, OneTest™ for Cancer™ AI</description>
</item>
<item>
<title>20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol "AIDX" Following 3 Consecutive Years of Sales Growth</title>
<link>https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-debuts-trading-on-nasdaq-under-ticker-symbol-aidx-following-3-consecutive-years-of-sales-growth</link>
<guid isPermaLink="true">https://6ix.com/company/2020-biolabs-inc-common-stock/news/2020-biolabs-debuts-trading-on-nasdaq-under-ticker-symbol-aidx-following-3-consecutive-years-of-sales-growth</guid>
<pubDate>Thu, 19 Feb 2026 14:00:00 GMT</pubDate>
<description>Company Ready to Scale Growth through OneTest™ AI-Powered Blood Tests for Cancer and Longevity GAITHERSBURG, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX), an early market leader in cutting-edge, AI-powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced its Class A ordinary shares will start trading today on the Nasdaq Capital Market under the ticker symbol “AIDX” capturing its mission of advancing AI pow</description>
</item>
</channel>
</rss>